SCHEMBL7220855

SCHEMBL7220855

CCOC(=O)CCNS(=O)(=O)c1cccc(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEP1B Q16820 1/20 0.58
AKR1C3 P42330 2/20 0.54
L3MBTL1 Q9Y468 3/20 0.54
MAPT P10636 4/20 0.49
ALDH1A1 P00352 7/20 0.49
LMNA P02545 3/20 0.49
POLB P06746 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.48
GAA P10253 2/20 0.48
RECQL P46063 1/20 0.48
ALOX15 P16050 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MTNR1B P49286 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7751590 0.94 MEP1B (0.53) MEP1BAKR1C3L3MBTL1MAPTALDH1A1
SCHEMBL11107020 0.89 AKR1C3 (0.60) MEP1BAKR1C3L3MBTL1MAPTALDH1A1
SCHEMBL7756199 0.88 MEP1B (0.56) MEP1BAKR1C3L3MBTL1MAPTALDH1A1
SCHEMBL10461985 0.87 AKR1C3 (0.58) MEP1BAKR1C3L3MBTL1MAPTALDH1A1
SCHEMBL3199069 0.84 ATM (0.64) MEP1BAKR1C3L3MBTL1MAPTALDH1A1
SCHEMBL2705227 0.83 ALDH1A1 (0.56) ALDH1A1LMNASMN1; SMN2KMT2AKDM4E
SCHEMBL7402207 0.82 MEP1B (0.65) MEP1BAKR1C3ALDH1A1LMNASMN1; SMN2
SCHEMBL15372683 0.80 MAPT (0.44) L3MBTL1MAPTALDH1A1SMN1; SMN2GAA
SCHEMBL30099024 0.80 MEP1B (0.64) MEP1BAKR1C3L3MBTL1MAPTALDH1A1
SCHEMBL2678034 0.80 ALDH1A1 (0.62) MEP1BAKR1C3L3MBTL1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6525074-B2 Peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras MERCK & CO., INC. 2003-02-25 US disclosed
US-20020049217-A1 Inhibitors of prenyl-protein transferase MERCK SHARP & DOHME CORP. 2002-04-25 US disclosed
US-6350755-B1 PEPTIDOMIMETIC COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY; THERAPY OF ARTERIOSCLEROSIS AND DIABETIC VASCULAR PATHOLOGIES; MERCK & CO., INC. 2002-02-26 US disclosed
WO-2001051128-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2001-07-19 WO disclosed
WO-2001051126-A1 INHIBITORS OF PRENYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049217-A1 Inhibitors of prenyl-protein transferase FNTA, KRAS, NRAS MEP1B 269/4885AKR1C3 1736/4885L3MBTL1 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.